Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
PluriSIn-1 (PluriSln 1; NSC-14613; NSC14613; NSC 14613) is a pluripotent cell-specific inhibitor with important biological activity. It is also a novel and potent inhibitor of the stearoyl-coA desaturase 1 (SCD1), which is able to selectively eliminate hPSCs.
ln Vitro |
Stearoyl-coA desaturase (SCD) on induced pluripotent stem cells (iPSCs)-derived cardiomyocytes (CM) is inhibited by PluriSIn 1, a small chemical. Notably, we show that treatment with PluriSIn 1 at 20 µM for one day dramatically causes the apoptosis of Nanog-positive induced pluripotent stem cells (iPSDs). Treatment with PluriSIn 1 also considerably reduces the mRNA and protein level of Nanog, a marker for both cell pluripotency and tumor growth. Furthermore, 4 days of 20 µM PluriSIn 1 treatment reduced Nanog-positive stem cells in cultured iPSD but did not increase apoptosis of iPS-derived CM. We intramyocardially injected PluriSIn 1- or DMSO-treated iPSD in a mouse model of myocardial infarction (MI) to examine whether therapy with PluriSIn 1 inhibits tumorigenicity of iPSD following cell transplantation. Two weeks after injection, DMSO-treated iPSD easily developed Nanog-expressing tumors, which is avoided by administering PluriSIn 1. Furthermore, PluriSIn 1 therapy does not alter the expression of cardiac differentiation markers cTnI, α-MHC, or MLC-2v (P>0.05, n=4). Crucially, iPS-derived CM treated with PluriSIn 1 shows the capacity to engraft and endure in the infarcted myocardium[1].
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
[1]. Zhang L, et al. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle. 2014;13(5):762-71
|
Molecular Formula |
C12H11N3O
|
|
---|---|---|
Molecular Weight |
213.24
|
|
CAS # |
91396-88-2
|
|
Related CAS # |
|
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
|
SMILES |
O=C(C1C([H])=C([H])N=C([H])C=1[H])N([H])N([H])C1C([H])=C([H])C([H])=C([H])C=1[H]
|
|
InChi Key |
HUDWXDLBWRHCKO-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C12H11N3O/c16-12(10-6-8-13-9-7-10)15-14-11-4-2-1-3-5-11/h1-9,14H,(H,15,16)
|
|
Chemical Name |
N-phenylisonicotinohydrazide
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.6896 mL | 23.4478 mL | 46.8955 mL | |
5 mM | 0.9379 mL | 4.6896 mL | 9.3791 mL | |
10 mM | 0.4690 mL | 2.3448 mL | 4.6896 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.